BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said that it completed the previously announced agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The acquisition will strengthen BioMarin’s commercial portfolio, adding two new treatments to the company’s existing portfolio of medicines that target lysosomal storage diseases: Galafold® (migalastat), the first oral treatment for Fabry disease, and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat), a two-component therapy for Pompe disease.
Read the full article: BioMarin Completes Acquisition of Amicus Therapeutics //
Source: https://www.prnewswire.com/news-releases/biomarin-completes-acquisition-of-amicus-therapeutics-302754256.html